These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28654460)

  • 1. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model.
    Thomsen AM; Gulinello ME; Wen J; Schmiegelow K; Cole PD
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):e91-e96. PubMed ID: 28654460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model.
    Alexander TC; Simecka CM; Kiffer F; Groves T; Anderson J; Carr H; Wang J; Carter G; Allen AR
    Behav Brain Res; 2018 Jul; 346():21-28. PubMed ID: 29229546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
    Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
    Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine.
    Li Y; Vijayanathan V; Gulinello M; Cole PD
    Pharmacol Biochem Behav; 2010 Jun; 95(4):428-33. PubMed ID: 20332001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment persists at least 1 year after juvenile rats are treated with methotrexate.
    Wen J; Patel C; Diglio F; Baker K; Marshall G; Li S; Cole PD
    Neuropharmacology; 2022 Mar; 206():108939. PubMed ID: 34986414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
    Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
    Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
    Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
    Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
    Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia.
    Levinsen M; Harila-Saari A; Grell K; Jonsson OG; Taskinen M; Abrahamsson J; Vettenranta K; Åsberg A; Risteli J; Heldrup J; Schmiegelow K
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):602-609. PubMed ID: 27571129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
    Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
    Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
    Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
    Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist.
    Vijayanathan V; Gulinello M; Ali N; Cole PD
    Behav Brain Res; 2011 Dec; 225(2):491-7. PubMed ID: 21856332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
    Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
    Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
    Parasole R; Menna G; Marra N; Petruzziello F; Locatelli F; Mangione A; Misuraca A; Buffardi S; Di Cesare-Merlone A; Poggi V
    Leuk Lymphoma; 2008 Aug; 49(8):1553-9. PubMed ID: 18766969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
    Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection].
    Guillaume C; Vegas H; Pastuszka A; Le Brun C; Lanotte P
    Ann Biol Clin (Paris); 2018 Oct; 76(5):568-570. PubMed ID: 30154068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
    Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
    Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
    J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.